Reply to Skowronski et al

Melissa K. Andrew; Shelly A. McNeil

doi:10.1093/infdis/jix549

Reply to Skowronski et al

Melissa K. Andrew, Shelly A. McNeil

Medicine

Medicine

Résultat de recherche: Letter › examen par les pairs

Langue d'origine	English
Pages (de-à)	169
Nombre de pages	1
Journal	Journal of Infectious Diseases
Volume	217
Numéro de publication	1
DOI	https://doi.org/10.1093/infdis/jix549
Statut de publication	Published - janv. 1 2018

Note bibliographique

Funding Information:
M. K. A. reports grant funding from GSK, Pfizer and Sanofi Pasteur. S. A. M. reports payments from the GSK group of companies, during the conduct of the study; and reports payments from Pfizer, Merck, Novartis and Sanofi, outside the submitted work.

ASJC Scopus Subject Areas

Immunology and Allergy
Infectious Diseases

PubMed: MeSH publication types

Journal Article
Comment

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.1093/infdis/jix549

Autres fichiers et liens

Citer

@article{e1437227ee1d4a0384fd5221a7c6c33d,

title = "Reply to Skowronski et al",

author = "Andrew, {Melissa K.} and McNeil, {Shelly A.}",

note = "Funding Information: M. K. A. reports grant funding from GSK, Pfizer and Sanofi Pasteur. S. A. M. reports payments from the GSK group of companies, during the conduct of the study; and reports payments from Pfizer, Merck, Novartis and Sanofi, outside the submitted work.",

year = "2018",

month = jan,

day = "1",

doi = "10.1093/infdis/jix549",

language = "English",

volume = "217",

pages = "169",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Reply to Skowronski et al

AU - Andrew, Melissa K.

AU - McNeil, Shelly A.

N1 - Funding Information: M. K. A. reports grant funding from GSK, Pfizer and Sanofi Pasteur. S. A. M. reports payments from the GSK group of companies, during the conduct of the study; and reports payments from Pfizer, Merck, Novartis and Sanofi, outside the submitted work.

PY - 2018/1/1

Y1 - 2018/1/1

UR - http://www.scopus.com/inward/record.url?scp=85063306960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063306960&partnerID=8YFLogxK

U2 - 10.1093/infdis/jix549

DO - 10.1093/infdis/jix549

M3 - Letter

C2 - 29045703

AN - SCOPUS:85063306960

SN - 0022-1899

VL - 217

SP - 169

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 1

ER -